Physician profile
Charles E Mcminn
NPI 1831249838
$343.23
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $36.28 · 2021: $89.25 · 2023: $22.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $102.41 | 2019-2021 | |
| Celgene Corporation | $52.07 | 2019 | |
| Novartis Pharmaceuticals Corporation | $45.81 | 2019 | |
| Abbvie INC. | $31.60 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.52 | 2023 | |
| Sanofi-Aventis U.S. LLC | $18.88 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.38 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $16.33 | 2021 | |
| Allergan, INC. | $13.20 | 2020 | |
| Amarin Pharma, INC. | $13.19 | 2021 | |
| Lilly USA, LLC | $10.84 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Mcminn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.